AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04421937 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procedure: Neuromuscular Electrical Stimulation with TDT
Description: The skin to be treated will be cleaned and dried. NMES will be implemented with signals received from two channels. In the first channel, the upper electrodes will be placed horizontally just above the hyoid bone. This is the place where the cupping is felt when the finger is pressed right under the chin. In the second channel, the lower electrodes will be placed horizontally, just above the thyrohyoid muscle. This is the place where you can feel a cupping when pressed with your finger, on both sides of the apple in the larynx. The device will be set to start at the lowest power, with very short pulses of approximately 700 microseconds, at intervals of 1 second. The power will be gradually increased according to the device and the power that the patient feels vibration will be stopped. The power to be applied will not exceed 25 milliamps. NMES application and Traditional Dysphagia Therapy will be applied for 45 minutes a day, 5 days a week for 3 weeks.
Study NCT00991822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzolamide 2%
Study NCT00991822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol 0.5%
Study NCT04213586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Description: 35 g of whey protein (7 d/wk) during a 10-wk resistance training program (3 d/wk; 3 sets of 8-12 repetitions with an interval of 1-2 minutes between sets and exercises) involving the leg press, leg extension, and arm flexion exercises. The load will be adjusted weekly.
Study NCT04213586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen supplementation
Description: 35 g of collagen (7 d/wk) + 2 g of leucine during a 10-wk resistance training program (3 d/wk; 3 sets of 8-12 repetitions with an interval of 1-2 minutes between sets and exercises) involving the leg press, leg extension, and arm flexion exercises. The load will be adjusted weekly.
Study NCT00451568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg 2 tablets 2 times a day
Study NCT00451568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desorelle
Description: 1 tablet/day in 21 days
Study NCT03066570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded Exposure
Description: Graded Exposure in vivo (GEXP) is a second-generation cognitive-behavioural intervention, and is characterized by systematic and repeated exposure to feared movements, activities and/or sensations in order to decrease fear and subsequently increase physical activity.
Study NCT00107744 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy protein-milk protein-carbohydrate
Description: 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks
Study NCT00107744 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk protein-carbohydrate-soy protein
Description: 40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.
Study NCT00107744 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate-soy protein-milk protein
Description: 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks.
Study NCT04366570 — intervention group
Intervention type: OTHER
Intervention: clinical assessment of the shoulder and the cervical spine includes stress guideline tests
Description: As a result of statistical processing, we are planning to obtain the most sensitive and specific tests from the clinical examination protocol
Study NCT02758574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CDT without ultrasound acceleration
Description: A pulmonary arteriogram will be performed. Upon confirmation of the pulmonary embolus a standard infusion catheter will be placed within the clot. The catheter will be used for infusion of thrombolytics to treat/dissolve the pulmonary embolus.
Study NCT02758574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CDT with ultrasound acceleration
Description: A pulmonary arteriogram will be performed. Upon confirmation of the pulmonary embolus an infusion catheter that incorporates an ultrasound emitting wire will be placed within the clot. The catheter will be used for infusion of thrombolytics to treat/dissolve the pulmonary embolus. The wire will be connected to an ultrasound generating device.
Study NCT03625505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: tablet, oral
Study NCT03625505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: tablet, oral
Study NCT02359019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02359019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03609554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: The Pilates exercise programme was implemented over 6 weeks, with 2 sessions/week (55 minutes/session). The Pilates programme was conducted by the Physical Education teacher, who was certified in Pilates training. The Pilates programme began at the basic level, incorporating more difficult principles and exercises gradually. The sessions were divided into the warm-up (7 min), the main part (41 min), and the cool down (7 min). Tt concentrated on basic Pilates exercises involving the principal regions of the body (spine flexions, extensions and rotations; hip flexions, extensions and rotations; and shoulder abductions, adductions and rotations).
Study NCT02307747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Description: Blood samples will be collected every 4 hours during 24 h
Study NCT04590859 — intervention group
Intervention type: PROCEDURE
Intervention: Block performed
Description: Comparing block performed with penile blood flow
Study NCT04590859 — intervention group
Intervention type: DEVICE
Intervention: LMA placement
Description: Placement of LMA for airway securement
Study NCT02625194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Oxygen is supplied through suction port during bronchoscope-guided intubation.
Study NCT03008720 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Study NCT03008720 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functional electrical stimulation (FES)
Study NCT03008720 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation
Study NCT03909802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-and family management of diabetic foot ulcers programs
Description: The intervention combines self-management and family management focusing on behavioral changes in patients with diabetic foot ulcers. Self-management focuses on intensive health education of physical activities, diet, medication, foot care, and blood glucose control. Family management focuses on problem-solving, establishing roles, and effective involvement in providing care amid individuals suffering DFU.
Study NCT03909802 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual care
Study NCT02271750 — intervention group
Intervention type: PROCEDURE
Intervention: lumbar puncture
Description: for spinal fluid
Study NCT06130163 — intervention group
Intervention type: PROCEDURE
Intervention: endoscopic retrograde cholangiopancreatography
Description: endoscopical clearance of the common bile duct
Study NCT01484795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BILEVEL (Respironics)
Description: Bilevel was delivered by a Bipap® ventilator (Respironics Inc, Murrysville, PA), applied via facial mask, with inspiratory positive pressure (IPAP) of 20 cmH2O and expiratory positive airway pressure (EPAP) of 10 cmH2O.
Study NCT01484795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuos positive airway pressure (Respironics)
Description: CPAP was delivered by a ventilator (Respironics Inc, Murrysville, PA), applied via a facial mask, with expiratory positive airway pressure of 10 cmH2O.
Study NCT04318756 — intervention group
Intervention type: BEHAVIORAL
Intervention: Translation and cultural adaptation go the cancer worry scale
Description: To develop and validate the Italian version of Cancer worry scale using high risk subjects for familiarity/genetic predisposition and patients with premalignant lesions.
Study NCT03549234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erector Spinae (single injection)
Description: Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
Study NCT03549234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral (single injection)
Description: Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
Study NCT00406471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab (Lucentis)
Description: 500 microgram intravitreal injection for 8 months or 300 microgram intravitreal injection for 8 months
Study NCT00962585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00962585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: Eligible patients meeting all study entry criteria were randomly assigned to receive one of the following active treatments for 4 weeks:~* S-equol 10 mg BID (20 mg total daily dose)~* S-equol 50 mg BID (100 mg total daily dose)~* S-equol 150 mg BID (300 mg total daily dose)
Study NCT02323035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Headgear
Description: Investigative Headgear with CPAP Mask.
Study NCT01916499 — intervention group
Intervention type: OTHER
Intervention: 3 tesla magnetic resonance imaging findings; coronary artery status
Study NCT01916499 — intervention group
Intervention type: OTHER
Intervention: 3 tesla magnetic resonance imaging findings; ventricular function and morphology
Study NCT04166929 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haplo SCT with NK cells
Description: Patients in this arm receive haplo-SCT followed by one boost of NK cells one/two weeks after the transplant. Lymphocyte are collected by apheresis from the donor one-two weeks after BM harvest. CD3 negative/CD56 positive cells are selected by immunomagnetic columns (other lymphocytes are stored to be used as DLI)
Study NCT04166929 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haplo SCT
Description: Patients in this arm receive a standard haplo-SCT. All administerd therapies are the same as in other arm, except for the NK cell boost..
Study NCT03880318 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Joint Preserving Surgery in spasmodic flat foot
Description: extensor digitorum longus, peroneus brevis and tertius lengthening together with calcaneal osteotomies
Study NCT00840996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: perioperative intravenous lidocaine (2 mg/kg/h) with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
Study NCT00840996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: perioperative placebo IV saline infusion of 2 mg/kg/h with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
Study NCT02248961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Description: Starting dose of Kanarb (Fimasartan) is 60 mg, orally, once a day in the morning. The subjects will visit the clinical site every 4 weeks to measure Arterial blood pressure (ABP). The dose will be doubled in case if SBP ≥140 mmHg or DBP ≥90 mmHg at Visit 3 (Day 28) or at Visit 4 (Day 56).~If necessary, the dose of the study drug may be increased based on the assessment of patient's condition performed at the phone contact (Day14±3). Patient may be called for an unscheduled visit for treatment adjustment (decided individually, with possibility of dose titration as per investigator's judgment, indicated in source documents).~When possibilities are, the patient should be administrated by the study medication at the same time in the morning.
Study NCT02248961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Cozaar® (Losartan), manufactured by MERCK SHARP \& DOHME B.V., Netherlands, tablets 50/100 mg
Study NCT00763399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics (antibiophilus(Lactobacillus casei), bio-three)
Description: probiotics (antibiophilus(Lactobacillus casei), bio-three) 4x 10\^8CFU/day
Study NCT01520389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-151
Description: MM-151
Study NCT01520389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-151 + irinotecan
Description: MM-151 + irinotecan
Study NCT00852137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 (ingenol mebutate) Gel, 0.05%
Description: PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
Study NCT00852137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Vehicle Gel once daily for 2 consecutive days
Study NCT01900054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine besilate
Description: Two TAU-284 5mg tablets will be taken orally twice a day
Study NCT00517465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po bid
Study NCT00517465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1511
Description: Starting multiple doses of 100mg po bid escalated in subsequent groups of patients to potential maximum multiple dose of 1200mg po bid.
Study NCT04013958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Ketamine
Description: IV Ketamine 0.1 mg/kg with IV morphine -0.1 mg/kg with IM Sailne 0.9%
Study NCT04013958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM Ketamine
Description: IM Ketamine 0.3 mg/kg with IV morphine -0.1 mg/kg
Study NCT01784315 — intervention group
Intervention type: DRUG
Intervention: Artemisinin combination therapies (ACT)will be used for Chloroquine resistant P.vivax
Description: 4 tablets of ACT on 0,8,24,36,48 and 60 hours will be given for Chloroquine resistant P.vivax infection.
Study NCT01784315 — intervention group
Intervention type: DRUG
Intervention: Chloroquine and Primaquine
Description: Chloroquine:10mg/kg for day1,2 and 5mg/kg for day 3 Primaquine: 0.25mg/kg daily for 14 days.
Study NCT03518528 — intervention group
Intervention type: DRUG
Intervention: Estradiol 2 MG
Description: Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks
Study NCT03518528 — intervention group
Intervention type: DRUG
Intervention: Estradiol 100 µg
Description: transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks.
Study NCT02746575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol
Study NCT00674635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK3152314A
Description: Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose
Study NCT00674635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT04757467 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy neuro-rehabilitation
Description: Treatment interventions which will be used for this group Passive range of movement exercises. Therapeutic positioning of the lower limb. Strengthening exercise for the lower limb. Over-ground gait training 5 times a week for 4 weeks. First week= 30 min exercise Second week= 1hour exercise Third week= 1hour and 30 min exercise Fourth week= 2 hours exercise All the treatment protocols will be applied to the patient for 5 times a week for consecutive 4 weeks. Interventions will be performed in the clinic and through home-based exercises using patient education
Study NCT04757467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetition-CIMT
Description: In this group of patients, the CIMT technique will be used for treatment. Following tasks will be performed by the patient, the unaffected limb will be constrained using a tight knee brace for about3 hr.~* Sit-to-Stand~* Forward and Backward stepping~* Stair Climbing and Descending (only the first stair will be used)~* Side-to-Side stepping with the affected limb~Each task will be performed 10 times per session in the first week and 2 sessions a day. In the second week, each task will be performed 20 times per session for 2 sessions a day. In the third week, each task will be performed 30 times per session for 2 sessions a day.In the fourth week, each task will be performed 40 times per session for 2 sessions a day. The session will be held 5 days in a week for the period of consecutive 4 weeks. Total of 1000 repetitions of the above mentions tasks will be performed in 4 weeks' study time by every participant
Study NCT04757467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hour-CIMT
Description: A task that performed by the participants in this group will be the same as performed by the rep-CIMT group. The unaffected limb will be in constrained for 3 hours. (15) Sessions will be held 5 days in the week for a period of consecutive 4 weeks.
Study NCT02629068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PURPOSE
Description: The first week of the intervention will focus on welcoming everyone to the facebook group and laying down the ground rules for participation. Each additional week of the intervention will focus on a specific topic to promote discussion and learning of each particular skill; however, questions and discussions on other relevant topics are always welcome and encouraged.~Week 1: Welcome Week Week 2: SUD Basics Week 3: Problem of Stigma Week 4: Communication Skills Week 5: Parental Monitoring Week 6: Stress Management Week 7: Family and Valued Directions Week 8: Putting It All Together
Study NCT03917160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMS device
Description: EMS treatment will be performed
Study NCT00153946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edaravone
Description: 30mg/20mL vial, twice per day, not longer than two weeks
Study NCT01242176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 XX (Trial Formulation 2)
Description: one single dose tablet in the morning
Study NCT01242176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 (Final Formulation)
Description: one single film-coated tablet in the morning
Study NCT01296490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress test
Description: Stress test while running on a treadmill until exhaustion for 8-12 minutes. Blood will be drawn before, 5 minutes after and an hour after the test.
Study NCT01679613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: oral administration
Study NCT02612896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mass drug administration, praziquantel 10mg/kg
Description: see previous, in elimination study arm only
Study NCT02612896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: in all study arms, using village meetings, posters, pamphlets.
Study NCT03622385 — intervention group
Intervention type: OTHER
Intervention: DNA Methylation
Description: No intervention will be performed. Blood and tissue samples will be analyzed for biomarkers that may be used to develop a diagnostic panel for early detection and diagnosis of high grade serous epithelial ovarian cancer.
Study NCT03548064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT03548064 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Description: LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
Study NCT01886963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY - Unblinded use of SPY Elite
Description: Surgeon plans tissue advancement flaps with the aid of Spy Elite System imaging
Study NCT01886963 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control - Blinded use of SPY Elite
Description: Surgeon is blinded to Spy Elite imaging and plans tissue advancement flaps according to clinical judgment alone
Study NCT04529720 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological/Vaccine: Pertagen (aP BioNet)
Description: Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region.